NASDAQ:CRSP

CRISPR Therapeutics News Headlines

$51.54

-0.69 (-1.32%)

(As of 05/16/2022 04:00 PM ET)

Add

Compare

Today's Range: $50.48
▼
$53.14
50-Day Range: $43.23
▼
$69.51
52-Week Range: $42.51
▼
$169.76

Volume: 1.28 million shs
Average Volume: 1.55 million shs
Market Capitalization: $3.99 billion

P/E Ratio: 14.28
Dividend Yield: N/A
Beta: 2.05

Get CRISPR Therapeutics News Delivered to You Automatically

Media Mentions By Week

CRISPR Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRSP
News Sentiment
▼
-0.41

0.48
▲
Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRSP Articles
This Week
▼
37

3
▲
CRSP Articles
Average Week

CRISPR Therapeutics (NASDAQ:CRSP) News Headlines Today

Source

Source	Headline
	CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $122.00 at Needham & Company LLC marketbeat.com - May 13 at 12:30 PM
	Jefferies Financial Group Equities Analysts Decrease Earnings Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP) marketbeat.com - May 12 at 6:22 AM
	3 Best Life Sciences Stocks to Buy Now (CRSP) marketbeat.com - April 8 at 12:25 PM
	CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed Drugs finance.yahoo.com - May 16 at 4:07 PM
	CRISPR Therapeutics Announces the Appointment of Phuong Khanh Morrow, M.D., FACP, as Chief Medical Officer finance.yahoo.com - May 16 at 4:07 PM
	Needham & Company LLC Cuts CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $122.00 americanbankingnews.com - May 16 at 6:06 AM
	CRISPR Therapeutics AG Shares Close the Day 12.2% Higher - Daily Wrap nasdaq.com - May 14 at 3:55 PM
	Equities Analysts Offer Predictions for CRISPR Therapeutics AG's Q2 2022 Earnings (NASDAQ:CRSP) americanbankingnews.com - May 13 at 2:22 AM
	William Blair Comments on CRISPR Therapeutics AG's Q2 2022 Earnings (NASDAQ:CRSP) americanbankingnews.com - May 13 at 2:22 AM
	Q2 2022 EPS Estimates for CRISPR Therapeutics AG (NASDAQ:CRSP) Cut by Analyst americanbankingnews.com - May 13 at 2:22 AM
	CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $99.00 americanbankingnews.com - May 12 at 4:38 AM
	CRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $85.00 americanbankingnews.com - May 12 at 4:38 AM

	FY2024 EPS Estimates for CRISPR Therapeutics AG Decreased by Analyst (NASDAQ:CRSP) americanbankingnews.com - May 12 at 2:34 AM
	Equities Analysts Set Expectations for CRISPR Therapeutics AG's FY2024 Earnings (NASDAQ:CRSP) americanbankingnews.com - May 12 at 2:34 AM
	Chardan Capital Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $168.00 americanbankingnews.com - May 12 at 1:56 AM
	Why did CRISPR Therapeutics stock rise today? Speculation as acquisition target seekingalpha.com - May 10 at 5:29 PM
	CRISPR stock draws flurry of price target cuts following Q1 result seekingalpha.com - May 10 at 12:28 PM
	CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss Estimates finance.yahoo.com - May 10 at 12:28 PM
	CRISPR Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results finance.yahoo.com - May 9 at 4:20 PM
	CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week Low at $46.62 americanbankingnews.com - May 8 at 3:45 AM
	Vertex: Q1 Results Solid, If Unspectacular, But Pipeline Progress Makes Bull Case seekingalpha.com - May 7 at 12:22 AM
	First Week of June 24th Options Trading For CRISPR Therapeutics (CRSP) nasdaq.com - May 6 at 2:02 PM
	Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked finance.yahoo.com - May 6 at 2:02 PM
	CRISPR Therapeutics (NASDAQ:CRSP) Now Covered by Credit Suisse Group americanbankingnews.com - May 2 at 5:40 AM
	Credit Suisse Group Initiates Coverage on CRISPR Therapeutics (NASDAQ:CRSP) americanbankingnews.com - May 2 at 5:08 AM
	What 4 Analyst Ratings Have To Say About CRISPR Therapeutics markets.businessinsider.com - April 28 at 2:13 PM
	CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of "Buy" by Brokerages americanbankingnews.com - April 28 at 2:42 AM
	3 Ominous Reasons to Avoid This Biotech Pioneer finance.yahoo.com - April 19 at 7:44 AM
	Is Now the Time to Bet on This Game-Changing Stock? finance.yahoo.com - April 14 at 8:41 AM
	CRISPR Therapeutics Proposes New Appointment to the Board of Directors finance.yahoo.com - April 12 at 4:38 PM
	Hedge Funds Love These 10 Undervalued Mid-Cap Stocks finance.yahoo.com - April 12 at 11:38 AM
	Interesting CRSP Put And Call Options For May 27th nasdaq.com - April 8 at 12:00 PM
	3 Ultra-Popular Stocks That Could Soar 120%, 51%, and 109%, Wall Street Says finance.yahoo.com - March 26 at 9:10 AM
	Cathie Wood’s 10 Stock Picks for the Next 5 Years finance.yahoo.com - March 21 at 4:25 PM
	Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today benzinga.com - March 16 at 2:14 PM
	Why CRISPR Therapeutics Stock Soared This Week finance.yahoo.com - March 11 at 8:20 PM

	Intellia Stock Has Tumbled. There Are Issues With Gene-Editing Patents. finance.yahoo.com - March 9 at 12:58 PM
	Harvard, MIT Win CRISPR Patent Dispute Against Berkeley finance.yahoo.com - March 1 at 8:16 PM
	Broad Institute wins breakthrough CRISPR patent ruling bizjournals.com - March 1 at 10:04 AM
	Patent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists finance.yahoo.com - March 1 at 10:04 AM
	10 Innovative Stocks in Cathie Wood’s Portfolio That Failed to Impress finance.yahoo.com - February 28 at 12:25 PM
	CRISPR Therapeutics GAAP EPS of -$1.84 misses by $0.10, revenue of $12.9M beats by $10.65M seekingalpha.com - February 15 at 6:15 PM
	CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results finance.yahoo.com - February 15 at 6:15 PM
	CRISPR Therapeutics to Participate in the 11th Annual SVB Leerink Global Healthcare Conference finance.yahoo.com - February 9 at 8:09 AM
	Why CRISPR Therapeutics Stock Fell 15.9% Last Month and Continues to Fall finance.yahoo.com - February 8 at 12:06 PM
	CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) finance.yahoo.com - February 2 at 10:01 AM
	Crispr Therapeutics begins dosing patients in Phase 1 trial for experimental type 1 diabetes treatment finance.yahoo.com - February 2 at 10:01 AM
	3 Green Flags for CRISPR Therapeutics' Future finance.yahoo.com - January 26 at 9:30 AM
	CRISPR Therapeutics AG Common Shares (CRSP) nasdaq.com - January 22 at 6:09 PM
	Arlington Financial Advisors, LLC Buys FIRST TR EXCHANGE, Apple Inc, iShares MSCI All Country ... finance.yahoo.com - January 18 at 9:57 AM
	CRSP: Investors Pumped by Unique Price Point, Intriguing Pipeline nasdaq.com - January 9 at 8:18 AM
	4 Biotechs That Could Be Potential Takeover Targets in 2022 finance.yahoo.com - December 30 at 9:32 AM
	CRISPR Therapeutics (NASDAQ:CRSP) shareholders are still up 280% over 5 years despite pulling back 5.0% in the past week nasdaq.com - December 28 at 9:26 AM

Get CRISPR Therapeutics News Delivered to You Automatically

This page was last updated on 5/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources